8-K: Alumis Reports Strong 2025 Results, Positive Phase 3 Psoriasis Data

Alumis Inc. announced its year-end 2025 financial results, highlighted by positive Phase 3 data for envudeucitinib in plaque psoriasis and a significant capital raise.

Summary

• Reported year-end 2025 financial results, including a net loss of $243.3 million, an improvement from $294.2 million in 2024.
• Achieved positive topline results from Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis.
• Envudeucitinib met all primary and secondary endpoints with high statistical significance, demonstrating approximately 65% of patients achieving PASI 90 and over 40% achieving PASI 100 at Week 24.
• Envudeucitinib showed a favorable safety and tolerability profile consistent with the Phase 2 program.
• Completed an upsized public offering in January 2026, raising $345.1 million in gross proceeds ($324.4 million net proceeds).
• Anticipates submitting a New Drug Application (NDA) for envudeucitinib in PsO in the second half of 2026.
• Expects potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) in the third quarter of 2026.
• Cash, cash equivalents, and marketable securities totaled $308.5 million as of December 31, 2025.
• Existing cash and proceeds from the public offering are expected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by strong Phase 3 clinical data for envudeucitinib and a successful capital raise that significantly extends the company's financial runway, positioning it well for future development and potential commercialization.

Positives

• Positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis, meeting all primary and secondary endpoints with high statistical significance.
• Envudeucitinib demonstrated leading skin clearance for oral plaque psoriasis therapies, with approximately 65% of patients achieving PASI 90 and over 40% achieving PASI 100 at Week 24.
• A favorable safety and tolerability profile for envudeucitinib was observed, consistent with the Phase 2 program.
• Successful completion of an upsized public offering in January 2026, raising $345.1 million in gross proceeds, significantly strengthening the company's financial position.
• Net loss decreased to $243.3 million in 2025 from $294.2 million in 2024, indicating improved financial performance.
• Anticipated cash runway into the fourth quarter of 2027 provides financial stability for ongoing development.

Negatives

• Research and development expenses increased significantly to $386.0 million in 2025 from $265.6 million in 2024, primarily driven by contract research and clinical trial costs, including acceleration of Phase 3 ONWARD activities.
• General and administrative expenses rose to $91.9 million in 2025 from $35.2 million in 2024, mainly due to transaction and severance costs related to the merger with ACELYRIN.
• Total expenses related to the merger with ACELYRIN amounted to $39.7 million for the year ended December 31, 2025.

Risks

• Ability to advance envudeucitinib or other programs and to obtain regulatory approval of and ultimately commercialize clinical candidates.
• Timing, costs, and results of preclinical and clinical trials.
• Ability to fund development activities and achieve development goals.
• Ability to protect intellectual property.

Future Outlook

Alumis plans to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the second half of 2026. Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus (SLE) is anticipated in the third quarter of 2026. The company will provide an update on its unified TYK2 franchise development strategy, including additional indications and A-005's Phase 2 trial timing, in the second quarter of 2026. Alumis expects its existing cash and proceeds from the recent public offering to fund operations into the fourth quarter of 2027.

Management Comments

• "Alumis concluded a pivotal year marked by strong execution and the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis, underscoring the promise of TYK2 inhibition and envudeucitinib's highly differentiated clinical profile."
• "By maximally inhibiting TYK2 to block both IL-23 and IL-17 pathways, envudeucitinib delivered comprehensive disease control with rapid onset of action, high rates of skin clearance, and meaningful symptom improvements in our Phase 3 ONWARD program that reinforce our conviction in envudeucitinib's potential to transform the psoriasis treatment landscape."
• "We look forward to our clinical topline readout for our potentially pivotal LUMUS Phase 2b trial in SLE, anticipated in the third quarter of this year."
• "Importantly, the results of both psoriasis and SLE will potentially unlock envudeucitinib's pipelineinapill opportunity to leverage maximal TYK2 inhibition across multiple immune-mediated diseases."

Industry Context

StockSavvy.ai notes that the positive Phase 3 results for envudeucitinib position Alumis as a strong contender in the competitive market for immune-mediated disease therapies, particularly in psoriasis. The focus on maximal TYK2 inhibition to block both IL-23 and IL-17 pathways represents a differentiated approach that could offer superior efficacy compared to existing treatments or other TYK2 inhibitors. The "pipelineinapill" strategy, leveraging envudeucitinib across multiple indications like SLE, is a common and efficient development pathway for biopharma companies seeking to maximize asset value and reduce development risk.

Comparison to Industry Standards

• Envudeucitinib demonstrated "leading skin clearance for oral plaque psoriasis therapies," with approximately 65% of patients achieving PASI 90 and over 40% achieving PASI 100 at Week 24. This suggests a strong efficacy profile compared to other oral treatments in the psoriasis market, such as Bristol Myers Squibb's Sotyktu (deucravacitinib), which reported PASI 75 rates of 58.7% at Week 16 in its POETYK PSO-1 trial.
• The favorable safety and tolerability profile is consistent with the Phase 2 program, which is crucial for competitive positioning against other systemic therapies that may have more significant side effect profiles.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, extended cash runway, and potential for future regulatory approvals and commercialization. The capital raise, while dilutive, provides necessary funding for advanced development.
• Patients: Potential for a new, highly effective oral treatment option for moderate-to-severe plaque psoriasis and potentially systemic lupus erythematosus.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.
• Creditors: Improved financial stability and extended cash runway reduce immediate solvency concerns.

Next Steps

• Late-breaking oral presentation of additional Phase 3 data (ONWARD1 and ONWARD2) at the American Academy of Dermatology (AAD) Annual Meeting (March 27-31, 2026).
• Company management to participate in a virtual Key Opinion Leader (KOL) event featuring Dr. Andrew Blauvelt to discuss results from the Phase 3 ONWARD program.
• Anticipated ONWARD3 topline data and Phase 2, two-year safety data (2H 2026).
• NDA submission for envudeucitinib in PsO (2H 2026).
• Potentially pivotal Phase 2b SLE topline data (3Q 2026).
• Update on unified TYK2 franchise development strategy, including evaluation of additional indications and timing for A-005's Phase 2 trial (2Q 2026).
• Completion of strategic review for lonigutamab (1H 2026).
• Initiate Phase 1 trial for next clinical candidate (new target) (2H 2026).

Key Dates

Recommendation

The positive Phase 3 results for envudeucitinib in psoriasis, demonstrating leading skin clearance and a favorable safety profile, are a significant de-risking event for Alumis. This, combined with the successful capital raise extending the cash runway into Q4 2027 and upcoming pivotal data for SLE, positions the company for substantial growth. The potential for envudeucitinib to be a "pipeline-in-a-pill" across multiple immune-mediated diseases further enhances its long-term value proposition, making it a compelling investment opportunity.

Keywords

Alumis, ALMS, biopharma, TYK2 inhibitor, envudeucitinib, plaque psoriasis, systemic lupus erythematosus, SLE, Phase 3 results, NDA submission, clinical trials, immunology, drug development, public offering, financial results